Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals (TERN) Total Current Liabilities (2020 - 2023)

Terns Pharmaceuticals' Total Current Liabilities history spans 4 years, with the latest figure at $12.1 million for Q3 2023.

  • For Q3 2023, Total Current Liabilities rose 61.57% year-over-year to $12.1 million; the TTM value through Sep 2023 reached $12.1 million, up 61.57%, while the annual FY2022 figure was $8.5 million, 24.16% up from the prior year.
  • Total Current Liabilities reached $12.1 million in Q3 2023 per TERN's latest filing, down from $14.2 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $22.8 million in Q4 2020 to a low of $5.8 million in Q2 2021.
  • Average Total Current Liabilities over 4 years is $9.8 million, with a median of $7.9 million recorded in 2021.
  • Peak YoY movement for Total Current Liabilities: crashed 70.12% in 2021, then surged 135.57% in 2023.
  • A 4-year view of Total Current Liabilities shows it stood at $22.8 million in 2020, then tumbled by 70.12% to $6.8 million in 2021, then increased by 24.16% to $8.5 million in 2022, then skyrocketed by 42.74% to $12.1 million in 2023.
  • Per Business Quant, the three most recent readings for TERN's Total Current Liabilities are $12.1 million (Q3 2023), $14.2 million (Q2 2023), and $12.1 million (Q1 2023).